Elucidation of the establishment of prostatic antigen presenting ability in dendritic cells, and development of novel medicines

• Project/Area Number: 15H04974
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: Nasu Yasutomo 岡山大学, 医歯薬学総合研究科, 教授 (20237572)
• Co-Investigator(Kenkyū-buntansha): 渡邉 豊彦 岡山大学, 医歯薬学総合研究科, 准教授 (30432644) ; 植木 英雄 岡山大学, 医学部, 技術専門職員 (90537218)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000); Fiscal Year 2017: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2016: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2015: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
• Keywords: 前立腺癌 / 癌抗原 / 免疫原性 / 腫瘍学 / 抗癌免疫

Outline of Final Research Achievements

In this study, we aimed to elucidate the establishment of prostatic antigen presenting ability in dendritic cells. Using our original fusion proteins consisted of prostatic antigens (PAP, PSA, Prostate specific membrane antigen, Melanoma associated antigen-A4, Extracellular matrix metalloproteinase inducer) and cytokines, and cancer-bearing mouse models, we disclosed that the induced antigen-specific antibody may be involved in the cancer suppressive effects. We are now establishing the in vitro and in vivo research systems focusing the endocytosis and intracellular localization of MHC class 1 and class 2, and cancer-antigen crosspresentation. We further continue this research to develop novel medicines for prostate cancer in terms of the anti-cancer immunitiy.

Research Products

• [Journal Article] Promising therapeutic efficacy of a novel REIC/Dkk-3 expressing adenoviral vector for hepatocellular carcinoma. (2017)
  • Author(s): Sawahara H, Shiraha H, Uchida D, Kato H, Kato R, Oyama A, Nagahara T, Iwamuro M, Horiguchi S, Tsutsumi K, Mandai M, Mimura T, Wada N, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Watanabe M, Sakaguchi M, et al.
  • Journal Title: J Gastroenterol Hepatol. Volume: - Issue: 10 Pages: 1769-1777
  • DOI: 10.1111/jgh.13757
  • Peer Reviewed / Open Access
• [Journal Article] A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment (2015)
  • Author(s): Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H.
  • Journal Title: Oncology Reports Volume: 33 Issue: 4 Pages: 1585-1592
  • DOI: 10.3892/or.2015.3770
  • Peer Reviewed / Open Access
• [Journal Article] Synergistic anti-pancreatic cancer immunological effects by treatment with REIC/DKK3 protein and peripheral blood mononuclear cells. (2015)
  • Author(s): Uchida D, Shiraha H, Kato H, Sawahara H, Nagahara T, Iwamuro M, Kataoka J, Horiguchi S, Watanabe M, Takaki A, Nouso K, Nasu Y, Kumon H, Yamamoto K
  • Journal Title: J Gastroenterol Hepatol Volume: - Issue: 6 Pages: 1154-1159
  • DOI: 10.1111/jgh.13259
  • Peer Reviewed / Open Access